Millipore Corporation (NYSE:MIL), a Life Science leader providing technologies, tools and services for bioscience research and biopharmaceutical manufacturing, introduces its new Mobius CellReady 3L Bioreactor. Co-developed under an agreement with Applikon Biotechnology, this ready-to-use three liter bioreactor requires no incremental capital investment, eliminates downtime and increases efficiency during process development.
“With the Mobius CellReady Bioreactor, process development scientists have a benchtop, single-use bioreactor that eliminates the time spent cleaning, sterilizing, and assembling glass bioreactors,” said Andrew Bulpin, Ph.D., Vice President, Upstream Processing, Millipore Corporation. “Unlike other products on the market, our disposable bioreactor works with most existing controllers so there is no new capital equipment or large bag systems to purchase.”
Millipore and Applikon Biotechnology announced an agreement in November 2008 to co-develop and distribute a disposable bioreactor solution. Designed to replace traditional glass benchtop bioreactors, the CellReady 3L Bioreactor has a standard stirred-tank format for use in development and optimization of cell culture processes. This vessel design provides a higher degree of predictability during process scale-up when compared to formats utilizing alternative vessel designs and agitation methods.
“The CellReady Bioreactor is the first and only single-use bioreactor that truly mimics the characteristics of conventional bioreactors,” said Arthur Oudshoorn, Managing Director, Applikon Biotechnology B.V. “Together with Millipore, we are delivering on the promise of stirred-tank, single-use bioreactors to increase the efficiency of process development scientists in the laboratory by eliminating downtime and making disposable bioreactors easier to use.”
About Millipore
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees in 30 countries worldwide. For more information, visit http://www.millipore.com.
About Applikon Biotechnology B.V.
Applikon Biotechnology B.V. (Schiedam, Netherlands) is a privately owned leading supplier of bioreactor systems for the pharmaceutical and the biotechnological market. We specialize in novel technologies in cultivation systems, measurement and control for the biopharmaceutical industry. In the past years, Applikon Biotechnology has built up a broad portfolio of unique bioprocessing devices for both cell culture and microbial cultivation, and this has considerably set us apart from the competition. We are definitely a step ahead.
Millipore
For Media:
Karen Marinella Hall, 978-715-1567
Director, Corporate Communications
karen_hall@millipore.com
or
For Investors:
Joshua Young, 978-715-1527
Director, Investor Relations
joshua_young@millipore.com
No comments:
Post a Comment